Galmed Pharmaceuticals (NASDAQ: GLMD) CAO reports shares, options and RSUs
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Galmed Pharmaceuticals Chief Accounting Officer Yohai Stenzler filed an initial ownership report showing direct holdings of 22,116 Ordinary Shares of GLMD. He also holds several equity awards and options that may convert into additional shares over time.
The filing lists options to purchase Ordinary Shares with an exercise price of 68.4000 per share, covering 222, 222, 111 and 222 underlying shares expiring between 2027 and 2030. Restricted share units include 2,083 units vesting on August 7, 2026, 23,333 units vesting in four installments from May 12, 2026 through November 12, 2027, and 25,000 units vesting between August 26, 2026 and August 26, 2028, all subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Stenzler Yohai
Role
Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Options to Purchase Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
Holdings After Transaction:
Options to Purchase Ordinary Shares — 222 shares (Direct);
Ordinary Shares — 22,116 shares (Direct);
Restricted Share Units — 2,083 shares (Direct)
Footnotes (1)
- These restricted share units vest on August 7, 2026, subject to the Reporting Person's continued service. These restricted share units vest in four equal installments on each of May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, subject to the Reporting Person's continued service. These restricted share units vest in accordance with the following vesting schedule: 1/3 shall vest on August 26, 2026 and the remaining portion shall vest in four equal installments on each of February 26, 2027, August 26, 2027, February 26, 2028 and August 26, 2028, subject to the Reporting Person's continued service.
FAQ
What does the Galmed (GLMD) Form 3 filing by Yohai Stenzler show?
The Form 3 shows Chief Accounting Officer Yohai Stenzler’s initial ownership in Galmed. He directly holds 22,116 Ordinary Shares, plus several option grants and restricted share units that may convert into additional shares if vested and, for options, exercised.
What stock options does the Galmed (GLMD) CAO hold according to the Form 3?
The CAO holds options to purchase Ordinary Shares at an exercise price of 68.4000, covering 222, 222, 111, and 222 underlying shares. These options expire between November 7, 2027 and November 10, 2030, providing long-dated equity incentives.
Are the equity awards in the Galmed (GLMD) Form 3 immediately vested?
No, the restricted share units vest over time. Schedules include single and installment vesting dates between May 12, 2026 and August 26, 2028, all subject to Yohai Stenzler’s continued service, aligning incentives with longer-term company performance.
Does the Galmed (GLMD) Form 3 indicate any recent insider buying or selling?
The Form 3 primarily reports existing holdings, not new trades. Transactions are coded as holdings with unknown transaction direction, indicating disclosure of current ownership rather than recent open-market purchases or sales by the Chief Accounting Officer.